Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Southwest Autism Research and Resource Center
mi
from
Phoenix, AZ
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Southwest Autism Research and Resource Center
mi
from
Phoenix, AZ
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
University of California, Davis Medical Center
mi
from
Sacramento, CA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
University of California, Davis Medical Center
mi
from
Sacramento, CA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
University of California Davis Cancer Center
mi
from
Sacramento, CA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
mi
from
Sacramento, CA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Pharmax Research Clinic
mi
from
Miami, FL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Pharmax Research Clinic
mi
from
Miami, FL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Lake Mary Pediatrics
mi
from
Orange City, FL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Lake Mary Pediatrics
mi
from
Orange City, FL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Institute for Juvenile Research
mi
from
Chicago, IL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Institute for Juvenile Research
mi
from
Chicago, IL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
James Whitcomb Riley Hospital for Children
mi
from
Indianapolis, IN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
James Whitcomb Riley Hospital for Children
mi
from
Indianapolis, IN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Kennedy Krieger Institute
mi
from
Baltimore, MD
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Kennedy Krieger Institute
mi
from
Baltimore, MD
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Umass Memorial Medical Center
mi
from
Worcester, MA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Umass Memorial Medical Center
mi
from
Worcester, MA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Univeristy of Missouri-Kansas City
mi
from
Kansas City, MO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Univeristy of Missouri-Kansas City
mi
from
Kansas City, MO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Seaver Autism Center, Mount Sinai Medical Center
mi
from
New York, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Seaver Autism Center, Mount Sinai Medical Center
mi
from
New York, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
New York State Institute for Basic Research in Dev. Disabilities
mi
from
Staten Island, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
New York State Institute for Basic Research in Dev. Disabilities
mi
from
Staten Island, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
University of North Carolina Hospital
mi
from
Chapel Hill, NC
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital
mi
from
Chapel Hill, NC
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Children's Hospital of Denver
mi
from
Denver, CO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Children's Hospital of Denver
mi
from
Denver, CO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Cutting Edge Research
mi
from
Oklahoma City, OK
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Cutting Edge Research
mi
from
Oklahoma City, OK
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Summit Research Network
mi
from
Portland, OR
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Summit Research Network
mi
from
Portland, OR
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Suburban Research Associates
mi
from
Media, PA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Suburban Research Associates
mi
from
Media, PA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Vanderbilt University Medical Center
mi
from
Nashville, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
mi
from
Nashville, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Red Oak Psychiatry Associates, P.A.
mi
from
Houston, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Red Oak Psychiatry Associates, P.A.
mi
from
Houston, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Road Runner Research
mi
from
San Antonio, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Road Runner Research
mi
from
San Antonio, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
Locomotor Training for Neurological Disease
Locomotor Training for Neurological Disease
Status: Archived
Kennedy Krieger Institute
mi
from
Baltimore, MD
Locomotor Training for Neurological Disease
Locomotor Training for Neurological Disease
Status: Archived
Updated: 1/1/1970
Kennedy Krieger Institute
mi
from
Baltimore, MD
Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy.
Status: Archived
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy.
Status: Archived
Updated: 1/1/1970
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
North Central Neurology Associates, PC
mi
from
Cullman, AL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
North Central Neurology Associates, PC
mi
from
Cullman, AL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
The Research & Education Inst. of Alta Bates Summit Med. Group
mi
from
Berkeley, CA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
The Research & Education Inst. of Alta Bates Summit Med. Group
mi
from
Berkeley, CA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Neuro-Pain Medical Center
mi
from
Fresno, CA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Neuro-Pain Medical Center
mi
from
Fresno, CA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Moores Cancer Center
mi
from
La Jolla, CA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Moores Cancer Center
mi
from
La Jolla, CA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Yale New Haven Medical Center
mi
from
New Haven, CT
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Yale New Haven Medical Center
mi
from
New Haven, CT
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Sunrise Clinical Research, Inc.
mi
from
Hollywood, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Sunrise Clinical Research, Inc.
mi
from
Hollywood, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
University of Florida Gainesville
mi
from
Gainesville, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
University of Florida Gainesville
mi
from
Gainesville, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
University of Miami Hospital
mi
from
Miami, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
mi
from
Miami, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Neurological Associates
mi
from
Pompano Beach, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Neurological Associates
mi
from
Pompano Beach, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Neurology Consultants of Burlington County
mi
from
Lumberton, NJ
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Neurology Consultants of Burlington County
mi
from
Lumberton, NJ
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
AMO Corporation
mi
from
Tallahassee, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
AMO Corporation
mi
from
Tallahassee, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
MS Center of Vero Beach
mi
from
Vero Beach, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
MS Center of Vero Beach
mi
from
Vero Beach, FL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
South Suburban Neurology
mi
from
Flossmoor, IL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
South Suburban Neurology
mi
from
Flossmoor, IL
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Neorological Associates
mi
from
Richmond, VA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Neorological Associates
mi
from
Richmond, VA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Mercy Ruan Neurology Clinic Res Ct.
mi
from
Des Moines, IA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Mercy Ruan Neurology Clinic Res Ct.
mi
from
Des Moines, IA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
University of Kansas Medical Center
mi
from
Kansas City, KA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
University of Kansas Medical Center
mi
from
Kansas City, KA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Johns Hopkins Hosp
mi
from
Baltimore, MD
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Johns Hopkins Hosp
mi
from
Baltimore, MD
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
University of Maryland, Baltimore
mi
from
Baltimore, MD
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
University of Maryland, Baltimore
mi
from
Baltimore, MD
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Caritas St. Elizabeth Medical Center
mi
from
Brighton, MA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Caritas St. Elizabeth Medical Center
mi
from
Brighton, MA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Springfield Neurology Associates, LLC
mi
from
Springfield, MA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Springfield Neurology Associates, LLC
mi
from
Springfield, MA
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Spectrum Health Medical Group, Neurology
mi
from
Grand Rapids, MI
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Spectrum Health Medical Group, Neurology
mi
from
Grand Rapids, MI
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Saint Luke's Hospital
mi
from
Chesterfield, MO
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program
Status: Archived
Updated: 1/1/1970
Saint Luke's Hospital
mi
from
Chesterfield, MO